NRx Pharmaceuticals reported quarterly EPS of $0.19, beating the Zacks consensus loss of $0.09 by $0.28 and reversing a year-ago loss of $0.30. The print represents a sizable YoY swing to profitability and a clear upside to analyst expectations, likely prompting a positive stock reaction.
NRx Pharmaceuticals reported quarterly EPS of $0.19, beating the Zacks consensus loss of $0.09 by $0.28 and reversing a year-ago loss of $0.30. The print represents a sizable YoY swing to profitability and a clear upside to analyst expectations, likely prompting a positive stock reaction.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
